A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Latest Information Update: 23 Nov 2025
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 16 Sep 2025 New trial record